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Abstract
BACKGROUND: Children and adolescents with type 1 diabetes (T1DM) can encounter a
variety of factors that affect proper management of their diabetes, including mental health. Youth
with diabetes have significantly higher rates of depression, anxiety, and mental health problems
compared to the general population. Anxiety is especially prevalent. PURPOSE: The objective
of this project was to evaluate anxiety screening of children and adolescents with T1DM during
their routine diabetes visits. Specifically, to assess for any trends in anxiety levels and patient
characteristics including demographics, insulin regimen and A1C levels. METHODS: A crosssectional, retrospective review of ambulatory electronic health records (AEHR) was conducted in
the Pediatric Diabetes Clinic at the Barnstable Brown Diabetes Center (BBDC), University of
Kentucky in Lexington, Kentucky. Records from October 1, 2019 to September 20, 2020 were
evaluated for utilization of the GAD-7 screening tool in children and adolescents with T1DM
during routine follow-up diabetes care. Patients from these records were on insulin therapy and
had been seen for routine, follow-up diabetes care. RESULTS: Overall, it was found that the
majority of adolescents screened were anxious. Statistically significant findings in association
with GAD-7 scores were found related to sex, years with a diabetes diagnosis and insulin
regimen. Females with T1DM were found to have higher GAD-7 scores compared to males with
T1DM. Children and adolescents who have been diagnosed longer and those on insulin pump
therapy were less anxious than those on multiple daily injection (MDI) therapy or shorter
duration of T1DM. CONCLUSIONS: A majority of children and adolescents with T1DM
screened for anxiety during routine follow-up of diabetes care were anxious. Findings support a
need for increased awareness of anxiety in the T1DM adolescent population. A need for
universal anxiety screening and interdisciplinary management is also supported.
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Anxiety Screening in Children & Adolescents with Type 1 Diabetes Using the GAD-7 Tool
Introduction
Children and adolescents with type 1 diabetes (T1DM) can encounter a variety of factors
that affect proper management of their diabetes, including mental health. Youth with diabetes
have significantly higher rates of depression, anxiety, and mental health problems compared to
the general population (Gallagher, 2017; Kanner, Hamrin & Grey, 2003). Anxiety is especially
prevalent. In the United States, among children aged 3-17 years, 7.1% (approximately 4.4
million) have been diagnosed with anxiety. Among children and adolescents with T1DM, rates
are estimated to be between 13-17% (Center for Disease Control and Prevention, “CDC”, 2020).
These statistics reinforce the importance of understanding anxiety and the impact it has on
children and adolescents with T1DM. The American Diabetes Association (ADA) recommends
addressing all psychosocial and mental health issues early to prevent complications in diabetes
management (“American Diabetes Association, “ADA”, 2018). Recommendations for children
diagnosed with diabetes include screening anxiety at diagnosis and yearly as part of their routine,
follow-up care.
Background
Mental health issues commonly described by adolescents with diabetes include fear of
hypoglycemia and hyperglycemia, anxiety, disordered eating behaviors and depressive
symptoms (ADA, 2018). Poor management of mental health issues are linked with worsening
diabetes outcomes including non-adherence, poor glycemic control, reduced quality of life and
higher rates of long-term diabetes complications (ADA, 2018). Anxiety, including frequently
worrying, in children and adolescents with T1DM can make diabetes self- management more
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difficult. Proper management of T1DM requires a complex and often demanding treatment
regimen. Daily requirements in self-management tasks can be overwhelming and stressful for
the child or adolescent with T1DM and their family. Many children and adolescents with
diabetes fear hypoglycemia in addition to common anxiety symptoms related to peer interactions
and academic performance. Any level of increased anxiety can have a negative impact on
diabetes control. Proper identification of mental health issues is extremely important.
With proper anxiety screening and identification, resources can be made available to
optimally manage any psychosocial complications. Children and adolescents struggling with
anxiety need available resources and support to properly care and manage their health into
adulthood. Children and adolescents with T1DM are set up for success when their mental health
and diabetes are managed together.
The Pediatric Diabetes Clinic at the University of Kentucky, Barnstable-Brown Diabetes
Center (BBDC) see about 700 children with diabetes each year in any one of four clinics
throughout the Commonwealth. Adolescents are a large portion of the population followed for
management of diabetes. Children and adolescents with T1DM, on insulin therapy, are routinely
seen at three month intervals for evaluation of current diabetes care and management. The
Generalized Anxiety Disorder -7 (GAD-7) screening tool (Figure 1) is administered to children
with diabetes, 11-21 years of age. This screening was implemented in 2019 and is provided at
least annually as part of routine care and follow-up management of T1DM.
Objective
The objective of this project was to evaluate anxiety screening of children and
adolescents with T1DM during their routine diabetes visits at University of Kentucky’s BBDC.
Screening for psychosocial distress and mental health problems is a prime component of proper
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diabetes management and care. It is hoped that by assessing anxiety rates in this specific
population, proper care will incur to not only better manage mental health but also diabetes
control. It is furthermore important to utilize a multidisciplinary team of specialists trained in
pediatric diabetes management, but also knowledgeable of the additional challenges for youth
with T1DM. There is no current data on the rates of anxiety or severity of anxiety symptoms
among children and adolescents with T1DM currently receiving care at UK's BBDC.
Specific Aims
At UK’s Division of Pediatric Endocrinology, the specific aims of this study were to evaluate the
following:
1. Trends in anxiety scores in children and adolescents with T1DM, aged 11 years to 21
years.
2. Demographic characteristics of children and adolescents with T1DM, aged 11 years 21 years who screened positive for anxiety.
3. Duration of T1DM, age at diagnosis, years with T1DM, A1C levels, treatment
regimen, and glucose monitoring activities of children and adolescents with T1DM, aged
11 years - 21 years who screened positive for anxiety.
This project is important to UK’s Division of Pediatric Endocrinology because of the increasing
prevalence of mental health concerns in the adolescent population with T1DM. Recent research
has highlighted trends with depression in this specific group, however anxiety is less understood.
Assessing trends between anxiety and diabetes management will provide better opportunities for
early intervention and interdisciplinary care to improve patient quality of life as it relates to
diabetes management and psychological health.
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The Iowa Model as the Theoretical Framework
The Iowa Model is a framework designed to address the implementation of evidencebased practice change to improve patient care and outcomes. The model helps to transition
research findings into clinical practice in hopes of improving patient outcomes (Brown, 2014).
The Iowa model allows providers to look at problem-focused or knowledge-focused triggers
where evidence-based practice may help. Screening for anxiety in youth with diabetes is a
knowledge focused idea, as new research findings are showing the alarming trend of mental
health concerns in adolescents with T1DM (ADA, 2018). Most research has focused on
depression rates in youth with T1DM, yet little has been explored regarding anxiety. The Iowa
model works step by step to identify if the issue at hand is priority for endocrine clinics and can
help to implement a plan for screening anxiety in such clinics. Therefore, by taking the steps of
the Iowa Model, it was determined that an EBP project assessing GAD-7 scores was needed and
important (Brown, 2014).
Generalized Anxiety Disorder 7 – Item Scale (GAD-7)
The Generalized Anxiety Disorder Assessment (GAD-7) is a seven-item screening tool
(Figure 1) that is used to measure and assess the severity of generalized anxiety disorder (GAD).
Each item asks individuals to rate the severity of their symptoms over the past two weeks. This
tool has been utilized frequently in primary care patients, the general population and adolescents.
Scoring allows providers to not only assess for presence of anxiety symptoms but also severity,
differentiating from minimal, mild, moderate to severe.
This screening tool is available in various languages with free access to use online.
Additionally, this is a self-administered tool and typically takes individuals one to two minutes to
complete. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3 to the responses
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“not at all”, “several days”, “more than half the days”, and “nearly every day”. Scores are added
together for the seven questions are and then assessed for severity. Total scores from adding all
seven answers range from 0-21. To interpret scores, 0–4 is minimal anxiety; 5–9 is mild anxiety
10–14 is moderate anxiety and 15–21 is severe anxiety. When used as a screening tool, further
evaluation is recommended when the score is 10 or greater.
An additional portion of this screening tool is a final question asking individuals how
difficult it is to do one’s work, take care of things at home, or get along with other people.
Options include not difficult at all, somewhat difficult, very difficult or extremely difficult. This
final portion serves as an adjunct to further assess for anxiety symptoms and severity. (Child
Outcomes Research Consortium, 2021).
Literature Review
A keyword search was utilized on University of Kentucky’s (UK) online library. The
university’s search function covers a large range of databases. Example keywords include
“diabetic adolescents”, “adolescents with Type I diabetes”, “diabetic youth”, “type I diabetes”
and “youth with type I diabetes”. Other keywords include “anxiety”, “mental health” and
“psychiatric health”. UK’s library search additionally provides suggested titles and keywords to
improve the search process. For example, “diabetic youth and anxiety” may have been searched
while UK suggested a research article regarding adolescents with diabetes and mental health.
Articles were further narrowed down by selecting only English written articles.
Additionally, articles were chosen that were published between 2005-2020, unless older articles
resulted that are gold standard to this specific issue. This search resulted in overall good quality
articles including case studies, cross-sectional studies, systematic reviews, population-based
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studies as well as general informative articles. These study types are overall high to medium
level evidence.
Synthesis of Evidence
There is an overwhelming amount of information supporting the link between higher
anxiety rates in adolescents with T1DM (Table 1). In conjunction with this, youth with both
diabetes and anxiety also show a strong tendency of having higher hemoglobin A1C levels, bad
glycemic control and poor quality of life (Adal et al., 2015; Almeida et al., 2018; Delamater,
2009; Gonder-Frederick et al., 2006; Hood et al., 2006 & Stah-Pehe et al., 2015). Strength of
this evidence is relatively strong. The only outlier with these results was one population-based
cohort study (2014) that took place in Holland; they found no link between adolescent diabetes
and increased rates of anxiety or any general mental health disorder (Silversten et al., 2014).
Two articles reported parental roles and the influence of their mental health on their
youths’ diabetes (Gonder-Frederick et al., 2006 & Herzer et al., 2009). Studies found that
adolescents are affected by their parents’ and caregivers’ personality, especially those who have
a tendency to be generally anxious (Delamater, 2009; Delamater et al., 1987 & Gonder-Frederick
et al., 2006). Primary recommendations from this literature review included the importance of
routine screening for mental health disorders, specifically anxiety and depression, in primary
care, but also diabetes clinics (Almedia et al., 2018; Delamater, 2009; Herzer et al., 2009, Hood
et al., 2006 & Stahel-Pehe et al., 2014). Strength of this evidence is relatively strong.
Gaps in Literature
Consistent results and relationships have also led to some consistent gaps in the literature.
Many highlighted the importance of utilizing a multi-disciplinary approach when caring for these
specific patients (Delamater, 2009; Delamater et al., 1987; Herzer et al, 2009 & Hood et al.,
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2006). However, no research exists delving into the results from such care. Therefore, literature
is needed on the positive effects of care that involves many providers, including mental health
specialists, primary care providers, endocrinologists and further.
Articles addressed parental involvement and influence on their adolescents’ diabetes care
but also tendency to have anxiety and other mental health issues. Further research is needed on
parental involvement, specifically their negativity and personal anxiety levels related to degree
of diabetes care (Gonder-Frederick et al., 2006). More research is also needed focusing on care
that involves parents’ and families’ role in their child’s overall care.
The largest literature gap involves routine screening of anxiety in the endocrine setting.
With common knowledge regarding this relationship between adolescent diabetes care and
higher rates of anxiety, studies are needed that assess the importance of anxiety screening and
outcomes when routine screening occurs. With proper screening and early recognition, the
relationship between anxiety in youth with T1DM and poor glycemic control can be better
understood.
Methods
Design
A cross-sectional, retrospective review of ambulatory electronic health records (AEHR)
was conducted. Records were reviewed for utilization of the GAD-7 screening tool and current
anxiety screening practices for children and adolescents with T1DM. Patients from these records
were on insulin therapy and had been seen for routine, follow-up diabetes care between October
1, 2019 to September 20, 2020 in the Pediatric Diabetes Clinic at the BBDC, University of
Kentucky in Lexington, Kentucky. Additionally, records were accessed from any of the three
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established, regional travel clinics. Only records obtained during this time period were reviewed
following IRB approval.
This study involved data evaluation for quality improvement assessment purposes to
determine additional needs for pediatric patients with T1DM and their support systems.
Information gathered from AEHR included demographics, age at type I diabetes diagnosis,
insulin therapy, glucose monitoring, A1C levels and co-existing conditions (Table 2). GAD-7
scores were also collected. Additionally, whether or not endocrine clinic visits occurred during
the COVID-19 pandemic were noted (Table 2).
Setting
Retrospective chart reviews were conducted at the Barnstable-Brown Diabetes Center
(BBDC) at UK Healthcare in Lexington, Kentucky. Initial establishment of pediatric diabetes
care occurs in the pediatric diabetes clinic located at UK Healthcare’s Turfland center. Routine
follow-up diabetes care may occur in the pediatric diabetes clinic in Lexington, Kentucky or any
of three regional travel clinics located throughout Appalachia in Kentucky (Monticello,
Barbourville, or Pikeville).
Sample
The sample for this study included electronic health records of children and adolescents
11 years to 21 years with T1DM followed at BBDC for diabetes care. This age range was
selected due to the validated age range associated with the GAD-7 screening tool. All electronic
health records of children and adolescents with T1DM seen for routine, follow-up diabetes care
between October 1, 2019 and September 20, 2020 were eligible for enrollment. The inclusion
criteria required for enrollment included the following: 1) 11 years -21 years of age, 2) T1DM
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diagnosis and use of insulin therapy, 3) documentation of completed GAD-7 screening tool in
AEHR, and 4) English as primary language.
Exclusion criteria include the following: 1) Not on insulin therapy 2) Ages 0-10 years or
greater than 21 years. 3) No evidence of completed GAD-7 screening tool available in AEHR, 4)
Not capable of completing the GAD-7 for themselves due to impairment from other disabilities,
5) emancipated minors, 6) those who are ward of the state, or 7) non-English as primary
language. No exclusions based on gender, A1C level, or duration of diabetes were made.
A total of 480 AEHR's were reviewed for inclusion into the study. There were 81
AEHR’s who met criteria.
Data Collection
Approval from the University of Kentucky Institutional Review Board (IRB) and the
Healthcare System’s Office of Research and Administration was obtained prior to data
collection. Providers at Barnstable Brown Diabetes Center (BBDC) annually screen for anxiety
in adolescent patients with T1DM using the GAD-7 scale. This is current provider practice. Once
adolescents have completed the scale, it is reviewed by the provider, discussed with the family,
and scanned into the child’s individual AEHR along with all other clinic visit documents. Office
staff at BBDC assisted in enrolling eligible electronic health records into the study. Patient
demographics, A1C levels, diabetes management regimen and GAD-7 scores were collected
(Table 2). The collected data was de-identified by a provider with password- protected access to
AEHR prior to being made available to the primary investigator.
Data available to the primary investigator did not include any of the 18 HIPAA personal
identifiers information. Specific study numbers were utilized by the provider collecting data in
lieu of patient names to ensure de-identification of protected health information (PHI) and
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maintain confidentiality. Necessary documentation for the study were documented on a separate
spreadsheet and all de-identified data was stored on a password protected computer (Figure 2).
Data Analysis
Data was evaluated by statistical analysis. The computer software program SPSS,
version 25 was specifically used. Descriptive statistics including means, standard deviation and
frequency distributions described patient demographics. Pearson’s correlation coefficient was
utilized to assess any correlation between two continuous variables. Selected variables that were
assessed for correlation included age, years with a DM1 diagnosis, A1C levels and GAD-7
scores. A p level of 0.05 was used for statistical significance throughout. The two sample t-test
was used to assess any associations among nominal variables and the GAD-7 score. This
included sex, insulin therapy, glucose monitoring and whether GAD-7 was taken during the
COVID-19 pandemic.
Results
Demographics
The average age of pediatric patients was 14.9 (SD=2.0; see Table 3). Ages ranged from
11 – 19 years old. The majority (57%) were female, with 43% male. Average age at DMI
diagnosis was 8.62 (SD=2.03) with a range between 0-16 years. Length of diabetes diagnosis
averaged at 6.19 years (SD = 4.21) and ranged 0-17 years.
Diabetes Regimen and A1C Levels
Multiple daily injection (MDI) was the more common insulin therapy (75.3%). Nearly
25% were using pump therapy (24.7%). Continuous glucose monitoring was used more
frequently, at 51.9% compared to those who did not at 48.1%. The average A1C amongst
adolescents was 9.08 (SD = 1.87) and ranged from 5.4 to the maximum read of 14%. Forty-one
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records (50.6%) reported no coexisting conditions. A wide range of coexisting conditions were
reviewed from the records, depression was highest at 14 (17.3%). Other conditions included
celiac disease (6.2%), ADHD (4.9%) and other (13.6%). (Table 3).
GAD-7 Results
The majority (44.4%) of adolescents were considered to have mild anxiety with a score
of 5-9. Almost 26%were considered moderately anxious, scoring between 10-12 on the GAD-7
screening tool. There were 12 (14.8%) who had minimal to no anxiety symptoms with a score
between 0-4. Lastly, 14.8% scored severe anxiety with a range between 15-21. The majority
(48.1%) of adolescents indicated they found it somewhat difficult to do work, take care of things
and get along with others. Over 28% (28.4%) found it ‘not difficult at all’, while 19.8% found it
‘very difficult’. A small amount (3.7%) found this to be ‘extremely difficult’. (Table 3).
COVID – 19 Pandemic
The majority (69.1%) of records screened during the study time frame did not occur
during the COVID-19 pandemic. Thirty percent (30.9%) were screened during COVID-19.
(Table 3).
Discussion
The purpose of this study was to evaluate anxiety screening of children and adolescents
with DM1 during their routine diabetes visit at University of Kentucky’s BBDC. Specifically,
any trends in GAD-7 scores in adolescents with a type I diabetes diagnosis, ages 11 years to 21
years old. Additionally, to assess demographic characteristics in those who screened positive for
anxiety. Information specific to T1DM was also evaluated in this study, including age at
diagnosis, years with T1DM, and treatment regimen including glucose monitoring activities. Of
the three objectives, statistical significance was found for gender, years with a diabetes
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diagnosis, and treatment regimen in regard to anxiety scores. Additionally, some key findings
were found. A major theme to note is the majority of these patients are anxious, only 14.8% of
adolescent records were considered to have minimal to no anxiety. Eighty-five percent (85.2%)
of the records scored mild to severe anxiety on the GAD-7 screening tool.
Demographics
The objective of examining age and GAD-7 scores showed to have no statistical
significance (p 0.46, see Table 4). This shows that no specific age has anxiety over others, but
displays that as a whole, patients 11 years old to 21 years old have anxiety symptoms.
Associations between sex and mean GAD-7 scores was statistically significant (p 0.04, see Table
5), with females’ average GAD-7 score at 10.4, compared to males at 7.5. This strongly
suggests that females are more anxious than males. Additionally, years of diabetes diagnosis
was correlated with anxiety levels (p of 0.034), which is statistically significant. This suggests
that those who have had a type I diabetes diagnosis longer are less likely to be anxious, and vice
versa with a new diagnosis.
Diabetes Regimen, Glucose Monitoring and A1C Levels
A1C levels showed no correlation with GAD-7 anxiety scores (p 0.22, see Table 4). This
suggests that regardless of how well controlled one’s diabetes is, average adolescents have some
level of anxiety. Associations between therapy and GAD-7 scores was statistically significant (p
0.009, see Table 5). Adolescents who utilized pump therapy had average GAD-7 scores of 7.57,
versus children who utilized MDI averaging at 9.91. This association strongly suggests that
adolescents who have insulin pumps are less likely to be anxious. Continuous glucose
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monitoring showed to have no statistical significance in regards to GAD-7 scores and anxiety
levels. Therefore, regardless if a child is able to continuously assess their glucose levels versus
spot checking, average adolescents assessed had some level of anxiety.
COVID-19
It was important to consider the potential that some adolescents may be experiencing
compounding anxiety due to the many life changes brought on by the COVID-19 pandemic.
However, taking the GAD-7 screening tool during the pandemic showed no statistical
significance (p 0.211, see table 5). The average score amongst records during COVID-19 was
8.75 compared to 10.12 of records before COVID-19. It is important to note that the majority
(69.1%) of records screened during the study time frame did not occur during the COVID-19
pandemic.
Limitations
Several limitations were highlighted from this study. Firstly, this is a small sample size
and records were reviewed from a single site. This potentially limits generalizability. Secondly,
GAD-7 scores were not assessed in comparison records who do not have a diabetes diagnosis.
Their scores would be a good correlation to assessing levels in solely adolescents with DMI.
Thirdly, it is hard to assess for and evaluate confounding factors. Adolescents may have
many reasons as to why they are feeling anxious. It may not only be related to their type I
diabetes diagnosis, but may be a result of their family environment, current school assignments
and stressors, genetics and further. The level of support from family and support systems can
further affect these children, as studies have shown that caregivers who are stressed about
managing diabetes affect their children as well (Delamater, 2009; Delamater et al., 1987 &
Gonder-Frederick et al., 2006).
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Additionally, COVID-19 is a large source of stress and change. There was no statistical
difference between records screened before and after the pandemic. However, only 25 of the 81
records took place during COVID-19. This is large limitation, as many are likely feeling
compounding stress during this time, however the small number of records made this association
hard to assess. Another limitation includes the GAD-7 screening tool itself; many adolescents
may not feel comfortable being truthful on such surveys. It is possible that symptoms were not
accurately accounted for as some youth may not want to discuss their mental health.
Implications for Future Practice
This study identifies recommendations for future research as well as care changes in
endocrine clinics. Highlighting upon the limitations, it would be important to not only assess
adolescents with T1DM, but also assess GAD-7 scores in children without a confounding
diagnosis. The scores would allow one to juxtaposition and further assess what the high anxiety
scores suggest. Additionally, it would be helpful to further assess anxiety by also administering
the Fear of Hypoglycemia Survey (FOH). This survey assesses how blood glucose levels affect
how adolescents behave as well as assesses their degree of worrying. With so many adolescents
in this study (85.2%) scoring mild to severe anxiety on the GAD-7, it would be very helpful to
assess if their worry stems mostly from their diagnosis or is a result of many factors.
As mentioned, it might further be helpful to assess parental roles, perceptions and
influences regarding their child’s diagnosis and compounding anxiety. The Screen for Child
Anxiety Related Disorders assessment (SCARED) evaluates parental awareness of their child’s
anxiety symptoms. Not only assessing parental thoughts on anxiety, but also how the adolescent
manages and handles their T1DM is important too. With proper support, it is hoped that children
would feel less anxious.
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With the knowledge gained from this project, an assessment of next steps in the
endocrine setting is also needed. A large goal to work towards is multidisciplinary care with not
only endocrine providers but also mental health specialists. Adolescent patients are set up for
success when mental health and diabetes are managed together, as youth feel empowered to
recognize their feelings and ask for help. Therefore, recommendations for future research would
not only involve further assessment of anxiety in the adolescent population, but also involved
other disciplines to best manage young patients. As mental health is incorporated, it is hoped
that these young patients will feel more supported and able to best manage their diabetes.
Conclusion
This study hopes to increase awareness of anxiety in the adolescent population with
T1DM. The main purpose was to assess trends between characteristics of adolescent patients
with a T1DM diagnosis and their GAD-7 scores. Females were found to be more anxious than
males while youth who have been diagnosed longer than others showed less anxiety.
Additionally, adolescents who utilized an insulin pump were on average less anxious than youth
who used MDI. Some expected correlations were not found to be statistically significant.
However, the large key theme acknowledged from this study was that the vast majority of
adolescent patients with T1DM are anxious. Therefore, goals from this project suggest the need
of further anxiety screening and interdisciplinary management. With mental health properly
managed as well, it is believed that there will be an improvement in diabetes care by adolescents
with T1DM. Most importantly, with better coping mechanisms and diabetes management, there
will ideally be a great boost in quality of life, leading to a healthy adulthood.
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Table 1. Synthesis Table to summarize findings

Study
author

Year

Mean Age

Study
Type

Intervention or
Relationship (between
DMI and HA or DMI/HA
and poor glycemic
control)

Adal et al.

2015

14.7

CS

R1, R2

SL

Almeida et
al.

2018

14

CCS

R1

SL (NSL for
R2)

Banks et
al.

2018

Between
18-28

Literature
review of
RCTs

R1

SL (in African
American
young adults)

Bernstein
et al.

2013

17.1

CS

R1, R2

SL

R1, R2

SL –
developed
suggestions
for screening

CCS

R1, R2, additionally
assessed difference in
coping mechanisms

SL – also
found
commonalities
with how
those with and
without
anxiety cope
with DM1

CCS

R1, R2, additionally
parental influence /
perception

SL – also
found link
with parental
anxiety

Delamater,
A.M.

2009

NA

Delamater
et al.

1987

GonderFrederick
et al.

15.36, plus
2006
parental
involvement

15.4

N/A -guideline
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Major Finding
that Addresses
your Question

RCT

Nothing Ventured Nothing
Gained online tool

Positive
intervention
for DMI QOL

CCS

R1, R2

NSL in R1,
SL in R2

CS

R2

SL

19.9

PBC

R1

NSL

Between
11-13

PBC

R1, R2

SL as well as
SL with QOL

Hackworth
et al.

2013

Between
13-18

Herzer et
al.

2009

Hood et al.

2006

15.6 plus
primary
caregivers
14.9

Silversten
et al.

2014

Stah-Pehe
et al.

2014

ABBREVIATION KEY: CCS = case control study; CS = cross-sectional; DMI = Type I
Diabetes diagnosis; HA= history of / or diagnosis of anxiety; NA = not applicable; NSL = no
significant relationship link; PBC = population based cohort; R1 = Relationship of DMI and
anxiety; R2 = Relationship of DMI and anxiety with poor glycemic control; RCT = Randomized
Controlled Trial; SL = strong relationship link (either RI or R2); QOL = quality of life
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Table 2. Data gathered from AEHR
Measures

Description

Level of
Data Source
Measurement

Demographics
Gender
Male, Female
Age
Age in years
Type I Diabetes Information
Age at diagnosis
Age in years when diagnosed with Type I
diabetes
Years with DM1
Length of current Type I diabetes diagnosis
Type of therapy
Insulin pump or multiple dose insulin
Continuous Glucose
Yes or no
monitoring
Hemoglobin A1C
A1C = average blood glucose levels for past 2Levels
3 months, as a percentage
Anxiety Scoring
Generalized anxiety
The GAD-7 score is calculated by assigning
disorder (GAD-7)
scores of 0, 1, 2, and 3 to the responses “not at
survey
all”, “several days”, “more than half the days”,
and “nearly every day”. Scores are added
together for the seven questions are and then
assessed for severity. Total scores from adding
all seven answers range from 0-21. To
interpret scores, 0–4 is minimal anxiety; 5–9 is
mild anxiety 10–14 is moderate anxiety and
15–21 is severe anxiety. When used as a
screening tool, further evaluation is
recommended when the score is 10 or greater.
COVID-19 Pandemic
Was routine endocrine Yes or no
visit during the
pandemic?
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Nominal
Interval/Ratio

Medical Records
Medical Records

Interval/Ratio

Medical Records

Interval/Ratio
Nominal
Binary

Medical Records
Medical Records
Medical Records

Interval/Ratio

Medical Records

Ordinal

Medical Records

Binary

Medical Records

Table 3. Descriptive summary of record characteristics (N = 81)
Mean (SD); range or n (%)
14.9 (2.0); 11-19

Age, years
Sex
Male
Female
Age at diagnosis
Year with diabetes
Therapy
Multiple Dose Insulin (MDI)
Pump
Continuous Glucose Monitoring (CGM)
Yes
No
A1C
Coexisting Conditions
ADHD
Asthma
Celiac disease
Depression
Growth Hormone Deficiency
Hyperthyroidism
Hypothyroidism
None
Other
Post-traumatic stress disorder
Seizures
GAD-7 Questions
1. Feeling nervous, anxious or on edge
2. Not being able to stop or control
worrying
3. Worrying too much about different things
4. Trouble relaxing
5. Being so restless that it is hard to sit still
6. Becoming easily annoyed or irritable
7. Feeling afraid, as if something awful
might happen

35 (43.2%)
46 (56.8%)
8.62 (2.03); 0-16
6.19 (4.21); 0-17
61 (75.3%)
20 (24.7%)
42 (51.9%)
39 (48.1%)
9.08 (1.87); 5.4-14.0
4 (4.9%)
1 (1.2%)
5 (6.2%)
14 (17.3%)
2 (2.5%)
1 (1.2%)
2 (2.5%)
41 (50.6%)
11 (13.6%)
1 (1.2%)
1 (1.2%)
1.48 (1.01)
1.02 (1.06)
1.31 (1.08)
1.14 (0.89)
1.05 (1.13)
2.01 (0.99)
1.20 (1.08)

GAD-7 score
Minimal
Mild
Moderate
Severe
Difficulty with doing your work, take care of
things, get along with others:

12 (14.8%)
36 (44.4%)
21 (25.9%)
12 (14.8%)
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Not difficult at all
Somewhat difficult
Very difficult
Extremely difficult
Patient seen during Covid-19 pandemic
Yes
No

23 (28.4%)
39 (48.1%)
16 (19.8%)
3 (3.7%)

25 (30.9%)
56 (69.1%)

Table 4. Correlations among continuous variables and GAD score
Correlation coefficient r (p)
Age
-0.08 (.46)
Years with diabetes
-0.24 (.034)
A1C
0.22 (.053)
Table 5. Associations among nominal variables and GAD -7 score
Mean GAD-7 Score
(SD)

Sex
Female
Male
Therapy
Multiple Dose Insulin
Pump
Continuous Glucose
Monitoring (CGM)
Yes
No
Patient seen during Covid-19
pandemic
Yes
No

p

.004
10.4 (4.7)
7.6 (3.9)
.009
9.92 (4.67)
7.57 (3.85)
.126
8.43 (3.98)
9.97 (4.99)
.211
10.12 (4.81)
8.75 (4.38)
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Figure 1. GAD-7 Screening Tool

(Anxiety & Depression Association of America, 2021)

30

Figure 2. Study Data Collection form

Case # _____________
Age ________ Gender ________
Age at Dx _______ Years with T1DM _______
Therapy: Pump _______ MDI _____ CGM use ______
Co-existing conditions/meds ________
A1c’s during collection period _____; _____; _____; ____
GAD responses:
1. ________
2. ________
3. ________
4. ________
5. ________
6. _______
7. ________
Total: _____/21
Difficulty with doing your work, take care of things, get along with others:
Not at all ___
Somewhat difficult ___
Very difficult ___
Extremely difficult ___
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